There’s been encouraging news about the Oxford Covid-19 vaccine this week from a trial involving about 1,000 people. But how great is the challenge in scaling up from making a few thousand doses of the vaccine to manufacturing two billion by the end of this year? Sandy Douglas of Oxford’s Jenner Institute explains how they plan to mass-produce the vaccine safely given the speed and magnitude of the scale up. A new kind of treatment for Covid-19 may come from an unlikely source: llamas and alpacas, the South American relatives of the camel. Camelids produce unusually small and simple antibodies against viruses, including the coronavirus. This feature may make these molecules an effective Covid-19 therapy. Jane Chambers reports on research in Chile and the UK.Also in the programme: Roland talks to Noah Rose and Lindy McBride of Princeton University about what has made just a few mosquito species evolve a preference for biting humans, and the theory that 800 million years ago. He also talks to Professor Kentaro Terada of Osaka University and David Kring of the Lunar and Planetary Institute in the USA about evidence that the Moon and the Earth were bombarded by a shower of asteroids which plunged the Earth into a global ice age – an event which may have changed the course of the evolution of life.(Image: A team of experts at the University of Oxford are working to develop a vaccine that could prevent people from getting Covid-19 Credit: Press Association)Presenter: Roland Pease
Producer: Andrew Luck-Baker
Folgen von Science In Action
335 Folgen
-
Folge vom 23.07.2020Making a Covid-19 vaccine for two billion people
-
Folge vom 16.07.2020How long do Covid-19 antibodies last?Science in Action looks at some of the latest research on the response of our immune system to infection by the coronavirus. Researchers at Kings College London find that protective antibodies appear to fade away after about three months following infection whereas a team at the Karolinska Institute has discovered that although antibodies may decline, other important players called T cells in our defences do not. Doctors Katie Doores and Marcus Buggert talk about the implications of these discoveries for the quest for a vaccine against the coronavirus. Roland Pease also talks to Dr Barney Graham of the National Institute of Allergy and Infectious Diseases in the United States about the results from the Phase 1 trial of a novel type of vaccine against the virus. NIAID have partnered with biotech company Moderna to produce the first mRNA vaccine in the Institute’s pandemic preparedness program. Biologist Dr Sonja Wild tells Roland about the remarkable fishing strategy devised by dolphins in Shark Bay, Australia. They chase fish into the empty shell of giant sea snails, then take the shells to the surface and tip the fish into their mouths. Dr Wild’s 7 years of research has revealed how the dolphins have learned to do this. (Image: Getty Images)Presenter: Roland Pease Producer: Andrew Luck-BakerCorrection: The audio of this edition has been edited since its initial broadcast. This was to correct an error in Barney Graham’s interview. The phase 3 of the Moderna mRNA vaccine trial is scheduled to begin on 27 July, not 27 January as originally broadcast.
-
Folge vom 09.07.2020Rwanda’s game changing coronavirus testAfrican scientists have developed a reliable, quick and cheap testing method which could be used by worldwide as the basis for mass testing programmes.The method, which produces highly accurate results, is built around mathematical algorithms developed at the African Institute for Mathematical Sciences in Kigali. We speak to Neil Turok who founded the institute, Leon Mutesa Professor of human genetics on the government coronavirus task force, and Wilfred Ndifon, the mathematical biologist who devised the algorithm.The virus is mutating as it spreads, but what does this mean? There is particular concern over changes to the spike protein, part of the virus needed to enter human cells. Jeremy Luban has been analysing this mechanism. So far he says ongoing genetic changes seem unlikely to impact on the effectiveness of treatments for Covid -19.And Heatwaves are increasing, particularly in tropical regions, that’s the finding of a new analysis by climate scientist Sarah Perkins – Kirkpatrick.Presenter: Roland Pease Producer: Julian SiddleMain image: People stand in white circles drawn on the ground to adhere to social distancing in Kigali, Rwanda, on May 4, 2020, Photo by Simon Wohlfahrt / AFP via Getty Images
-
Folge vom 02.07.2020Covid -19 and ChildrenStudies in Children who have been severely affected by Covid 19 in Italy, Britain and the US are showing the same thing – a range of symptoms linked to an overactive immune system. Elizabeth Whittaker from London’s Imperial College discusses the similarities in these cases and possible reasons for this syndrome with Shanna Kowalsky from Mount Sinai hospital in New York. How much should drugs for Covid 19 cost? Remdesivir which has shown promise against the virus has been priced at over $2000 for a course of treatment, but Drug price analyst Andrew Hill says the cost of production is actually below $10.And how about some really alternative energy? Marion Cromb at Glasgow University has run an experiment to simulate a spinning black hole. In theory a rocket sent to an equivalent real black hole could use its rotation as a power source(Image: Getty Images)Presenter: Roland Pease Producer: Julian Siddle